Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576779 · ClinicalTrials.gov registry record
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,101
- Enrollment target
NCT05576779 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,101 participants.
The verdict
NCT05576779 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,101 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
Interventions
- OTHER Ofatunumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,101 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05576779
The ClinicalTrials.gov registry entry for NCT05576779 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatunumab is the first listed.
NCT05576779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05576779 about?
NCT05576779 is a clinical study titled "Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.". This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
What is the current status of trial NCT05576779?
This trial is currently completed. The enrollment target is 2,101 participants. The study started on 2020-12-03. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT05576779?
The interventions under investigation include: Ofatunumab (OTHER).
Who is sponsoring clinical trial NCT05576779?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.